The AR inhibitor fidarestat is effective as adjuvant therapy to enhance doxorubicin sensitivity of colorectal cancer cells and to reduce cardiotoxicity associated with the drug.
Doses May Be Adjusted for Treating NSCLC Patients
Biosimilars and originator trastuzumab neoadjuvant therapy had a comparable effect on pathologic complete response rates.
New safety issues are detected in almost one-third of drugs approved by the US FDA in the first 3 years after approval.
Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.
A new CSTD significantly reduced surface contamination during a simulated antineoplastic hazardous drug administration when compared to baseline.
Long-acting NK-1 receptor antagonist rolapitant demonstrates significant efficacy in managing CINV in patients receiving HEC or MEC for cancer.
New data presented at the International Liver Congress 2017 suggest that nivolumab may produce long-term benefits in sorafenib-experienced patients with advanced HCC.
A common beta blocker, carvedilol, is found to have preventive properties against the sun-induced cell damage that leads to skin cancer.
Rubraca (rucaparib) received accelerated approval by the U.S. Food and Drug Administration for the treatment of patients with previously treated BRCA-positive ovarian cancer.
Leflunomide, an immunosuppressor FDA-approved for rheumatoid arthritis, is effective against breast cancer in mouse study.
Zoledronic acid and clodranate are the recommended bisphosphonates for the adjuvant treatment of postmenopausal patients with breast cancer.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.
I was surprised to see an order for arsenic recently. What is this being used for?
In his plenary lecture at 2016 SABCS, Peter P. Bach, MD, MAPP, reviewed the factors contributing to escalating drug prices and the significance of drug prices in the value of a cancer treatment regimen.
Rucaparib has been approved for the treatment of patients with advanced ovarian cancer who harbor a deleterious BRCA mutation.
What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?
In a multicenter, open-label, phase 2 study, researchers evaluated the activity and safety of vandetanib in patients with advanced RET-rearranged NSCLC.
There is a lot of talk about biosimilar drugs. What makes a drug a biosimilar?
Patients with cancer incur significant out-of-pocket costs before their Medicare drug benefits activate, and due to those costs, many patients with CML delayed starting their treatment.
A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.
How should side effects of the new checkpoint inhibitor drugs be managed?
Anti-HER2 Therapies Link With Heart Blood Vessel Development Explains Cardiovascular Side Effects of TrastuzumabAugust 03, 2016
Therapies targeting ErbB2 (HER2), such as trastuzumab (Herceptin), are often associated with cardiovascular side effects. ErbB2 was recently found to also be expressed by vascular endothelial cells, and is an example of how tissue growth and blood vessel patterning are integrated at the molecular level.
Chemotherapy agents are sometimes required to be administered in a specific sequence. What factors influence the need to follow a specific sequence?
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Although Drugs@FDA may be useful for validating trial primary outcomes found on ClinicalTrials.gov, Drugs@FDA lacked information on secondary outcomes and adverse events, including deaths, according to an analysis of data from 100 trials available on both websites.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
- Study Questions Safety of E-cigarettes vs Regular Tobacco Cigarettes
- Changes in Pulmonary Function Tests in Breast Carcinoma Patients Treated With Locoregional Post-mastectomy Radiotherapy: Results of a Pilot Study
- Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|